Brief: Morepen Laboratories Says USFDA Clears Masulkhana API Facility With Nil Form 483 Observations
17/04/2026 10:34
April 17 (Reuters) - Morepen Laboratories Ltd MORL.NS: USFDA CLEARS MASULKHANA API FACILITY WITH NIL FORM 483 OBSERVATIONS ANNOUNCES USFDA INSPECTION AT MASULKHANNA FACILITY WITH ZERO OBSERVATIONS Source text: ID:nBSE5VDB5R Further company coverage: MORL.NS ((Reuters.Briefs@thomsonreuters.com;;))
Recent news on Morepen Laboratories
See all newsBrief: Morepen Laboratories Says High Court Quashes Notice Seeking Recovery Of 1.18 Billion Rupees
India's Morepen Laboratories gains on U.S. FDA submission for Sitagliptin tablets
Brief: Morepen Laboratories Submits First U.S. ANDA For Sitagliptin Tablets USP In Three Strengths
Brief: Morepen Laboratories Ltd June-Quarter Consol Net Profit 563.5 Million Rupees
India's Morepen Laboratories slips after quarterly profit fall